Ravicti Approved for Urea Cycle Disorders
FRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.
These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia buildup can lead to coma, brain damage or death, the FDA said Friday in a news release.
Ravicti is a liquid taken three times daily with meals. It's been approved for people whose disorders cannot be managed by a protein-restricted diet or amino acid supplements alone, the agency said.
Ravicti was compared to another UCD drug in a clinical study involving 44 adults. The most common side effects of the new drug were diarrhea, flatulence and headache.
Ravicti is marketed by Hyperion Therapeutics, based in South San Francisco, Calif.
The U.S. National Library of Medicine has more about UCDs.
-- Scott Roberts
Health News TodayFeed
- Sugary Sodas, Fruit Punches May Raise Kidney Stone Risk: Study 05/15/2013
- Procedure for Incontinence in Women May Lose Effectiveness With Time 05/14/2013
- Vitamin D May Help Prevent Uterine Fibroids 04/17/2013
- New Procedure May Shrink Enlarged Prostate Without Surgery 04/15/2013
- High-Dose Statins Linked to Acute Kidney Damage 03/20/2013
- View More Kidneys and the Urinary System News
Take a Personalized Health Test
What's Causing Your Symptoms?
15 Ways To Get Better Medicine
People who are actively involved in their medical care stay healthier, recover quicker when they're ill, and live longer, healthier lives.